November's Diabetic Eye Disease Awareness Month comes to a close, but the fight for better vision doesn't! Study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME. https://lnkd.in/dWGSYQCz
